

In the Claims

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

Please cancel non-elected claims 42-87, 102 and 105-131 without prejudice or disclaimer. Please cancel pending claims 88-89, and 95.

Please amend pending claims 90-94, 96-97, 99-100, 103, and 104 as noted below.

1-87. (Cancelled)

88. (Cancelled).

89. (Cancelled).

90. (Currently Amended) The method of claim ~~88~~104, wherein the CpG oligonucleotide has a length of 8-30 nucleotides ~~phosphodiester backbone~~.

91. (Currently Amended) The method of claim ~~89~~90 or 104, wherein the CpG oligonucleotide has a phosphate modified backbone.

92. (Currently Amended) The method of claim ~~91~~90 or 104, wherein at least one of the nucleotides of the CpG oligonucleotide has a phosphorothioate backbone.

93. (Currently Amended) The method of claim ~~89~~104, wherein the CpG oligonucleotide is a stabilized oligonucleotide selected from the group consisting of nonionic DNA analogs, such as alkyl- and aryl-phosphonates, alkylphosphotriesters in which the charged oxygen moiety is alkylated, and oligonucleotides containing a diol, such as tetraethyleneglycol and hexaethyleneglycol.

94. (Currently Amended) The method of claim ~~88~~104, wherein the CpG oligonucleotide is a synthetic oligonucleotide.

95. (Cancelled).

96. (Currently Amended) The method of claim ~~88~~104, wherein the CpG oligonucleotide has less than 100 nucleotides.

97. (Currently Amended) The method of claim ~~88~~96, wherein the CpG oligonucleotide comprises the formula:



wherein the C is unmethylated and wherein X_1 , X_2 , X_3 and X_4 are nucleotides.

98. (Previously Added) The method of claim 97, wherein the formula is preceded on the 5' end by a T.

99. (Currently Amended) The method of claim ~~88~~96, wherein the CpG oligonucleotide is administered by a route selected from the group consisting of oral, transdermal, injection, intravenous, parenteral, intraperitoneal, and intrathecal.

100. (Currently Amended) The method of claim ~~88~~96, wherein the CpG oligonucleotide is administered with an oligonucleotide delivery complex.

101. (Previously Added) The method of claim 100, wherein the oligonucleotide delivery complex is selected from the group consisting of a sterol, a cholesterol, a lipid, a cationic lipid, a virosome, and a liposome.

102. (Cancelled)

103. (Currently Amended) The method of claim ~~88~~96, wherein the bacterial infection is caused by a bacteria selected from the group consisting of *Helicobacter pyloris*, *Borelia burgdorferi*, *Legionella pneumophilia*, *Mycobacteria*, *Staphylococcus aureus*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Listeria monocytogenes*, *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus* (viridans group), *Streptococcus faecalis*, *Streptobacillus moniliformis*, *Streptococcus* (anaerobic sps.), *Streptococcus pneumoniae*, *Streptococcus bovi*, *Campylobacter sp*, *Enterococcus sp*, *Haemophilus influenzae*, *corynebacterium diphtheriae*, *Erysipelothrix rhusiopathiae*, *Bacillus antracis*, *Clostridium*, *Enterobacter aerogenes*, *Klebsiella pneumoniae*, *Pasturella multocida*, *Bacteroides sp*, *Fusobacterium nucleatum*, *Treponema pallidum*, *Treponema pertenue*, *Leptospira*, and *Actinomyces israeli*.

104. (Currently Amended) A method for treating a bacterial infection in a subject, comprising: administering to a subject in need thereof a CpG oligonucleotide in an effective amount to treat the bacterial infection, wherein the CpG oligonucleotide has a stabilized backbone.

105-131. (Cancelled)

132. (New) The method of claim 103, wherein the bacterial infection is caused by a *Mycobacteria*.